- Stocks
- Healthcare
- NASDAQ: BEAM

Price (delayed)

$102.07

Market cap

$6.77B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.15

Enterprise value

$6.69B

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a

BEAM's equity has surged by 138% year-on-year and by 30% since the previous quarter

The EPS is up by 25% year-on-year but it has declined by 8% since the previous quarter

BEAM's quick ratio is down by 15% year-on-year but it is up by 3.9% since the previous quarter

The net income has declined by 11% since the previous quarter

The debt has grown by 4.4% from the previous quarter

What are the main financial stats of BEAM

Market
Valuations
Earnings

Shares outstanding

66.35M

Market cap

$6.77B

Enterprise value

$6.69B

Price to earnings (P/E)

N/A

Price to book (P/B)

11.64

Price to sales (P/S)

264,574.96

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

278,675.33

Revenue

$24,000

EBIT

-$407.73M

EBITDA

-$402.17M

Free cash flow

-$155.22M

Per share
Balance sheet
Liquidity

EPS

-$7.15

Free cash flow per share

-$2.5

Book value per share

$8.77

Revenue per share

$0

TBVPS

$14.36

Total assets

$893.08M

Total liabilities

$344.53M

Debt

$142.65M

Equity

$548.55M

Working capital

$549.28M

Debt to equity

0.26

Current ratio

5.27

Quick ratio

5.28

Net debt/EBITDA

0.21

Margins
Efficiency
Dividend

EBITDA margin

-1.68M%

Gross margin

100%

Net margin

-1.7M%

Operating margin

-1.41M%

Return on assets

-70.4%

Return on equity

-115.1%

Return on invested capital

-96.6%

Return on capital employed

-53.3%

Return on sales

-1.7M%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Beam Therapeutics stock price performed over time

Intraday

-0.04%

1 week

-5.49%

1 month

0.13%

1 year

254.66%

YTD

25.02%

QTD

-20.7%

How have Beam Therapeutics's revenue and profit performed over time

Revenue

$24,000

Gross profit

$24,000

Operating income

-$337.47M

Net income

-$407.73M

Gross margin

100%

Net margin

-1.7M%

Beam Therapeutics's operating margin has decreased by 11% QoQ

Beam Therapeutics's operating income has decreased by 11% QoQ

The net income has declined by 11% since the previous quarter

The net margin has contracted by 11% from the previous quarter

What is Beam Therapeutics's growth rate over time

What is Beam Therapeutics stock price valuation

P/E

N/A

P/B

11.64

P/S

264,574.96

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

278,675.33

The EPS is up by 25% year-on-year but it has declined by 8% since the previous quarter

BEAM's equity has surged by 138% year-on-year and by 30% since the previous quarter

The price to book (P/B) is 10% lower than the last 4 quarters average of 13.0

BEAM's price to sales (P/S) is 42% higher than its last 4 quarters average of 186195.4

How efficient is Beam Therapeutics business performance

The ROE has soared by 71% YoY and by 14% QoQ

The company's return on assets fell by 40% YoY but it rose by 17% QoQ

BEAM's ROIC is down by 26% YoY but it is up by 23% QoQ

The return on sales has declined by 11% since the previous quarter

What is BEAM's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BEAM.

How did Beam Therapeutics financials performed over time

The total assets is 159% more than the total liabilities

The total assets has soared by 198% YoY and by 29% from the previous quarter

Beam Therapeutics's total liabilities has increased by 27% QoQ

The debt is 74% less than the equity

BEAM's equity has surged by 138% year-on-year and by 30% since the previous quarter

The company's debt to equity has surged by 63% YoY but it fell by 19% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.